Datavault AI Inc. (NASDAQ: DVLT) announced an expansion of its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS), extending its PharmacyChain blockchain technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The amended agreement aims to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments. The initiative leverages a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the terms, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced transactions, replacing the preferred shares originally contemplated for tax optimization. The companies stated that this agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
Datavault AI, headquartered in Philadelphia, PA, is known for its AI-driven data experiences and asset valuation in the Web 3.0 environment. The company’s cloud-based platform, through its Acoustic Sciences and Data Sciences divisions, provides solutions including WiSA, ADIO and Sumerian technologies for spatial audio, and high-performance computing for data perception, valuation and secure monetization. The platform serves industries such as sports & entertainment, biotech, education, fintech, real estate, healthcare and energy. The Information Data Exchange enables Digital Twins and licensing of name, image and likeness by attaching physical objects to immutable metadata.
This expansion is significant as it moves Datavault AI’s technology into a high-growth market with potential for patient empowerment and new revenue models. By allowing patients to control and monetize their health data, the partnership addresses increasing demand for data privacy and interoperability in healthcare. The tokenization of real-world assets could streamline processes in clinical trials, wellness programs and remote monitoring. For Datavault AI, the deal provides a strategic stake in DataMEDS and a foothold in healthcare, while DataMEDS gains access to advanced blockchain and AI capabilities.
The global health and wellness market, projected to grow substantially, offers a large addressable opportunity for patient-controlled data solutions. The agreement also highlights the trend of blockchain integration in healthcare for secure data sharing and compliance with regulations like HIPAA. As digital health evolves, partnerships like this could set precedents for data ownership and monetization.
For more information, see the full press release at https://ibn.fm/vBAxH and updates on Datavault AI at https://ibn.fm/DVLT. Learn more about Datavault AI at https://dvlt.ai.
